LiverMultiScan as an alternative to liver biopsy to monitor autoimmune hepatitis in the National Health Service in England; an economic evaluation

Early economic modelling from NHS England’s Oxford AHSN found LiverMultiScan to be a cost-effective, noninvasive alternative to painful, invasive surveillance liver biopsy for monitoring autoimmune hepatitis (AIH) across disease stages, saving up to £336,926, thus lowering NHS costs and procedure burden while enabling repeatable follow-up in routine care.